Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

This study has been terminated.
Sponsor:
Collaborators:
Texas Children's Hospital
University of Pittsburgh
Children's Hospital of Pittsburg
Seattle Children's Hospital
Mayo Clinic
Brown University
Information provided by (Responsible Party):
Susan Blaney, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00074607
First received: December 16, 2003
Last updated: November 9, 2012
Last verified: November 2012
  Purpose

Subject's are being asked to take part in this study because he or she has a type of cancer that has spread to the meninges (tissues that cover the brain and spinal cord).

There is no known effective treatment for this specific disease or the subject has received all of the treatments that are known to work for his or her specific disease without success. Currently, there is no other effective treatment for this type of cancer.

The purposes of this study are:

  • to determine the highest dose of gemcitabine, an anti-cancer drug, that can safely be given directly into the spinal fluid of children and adults whose cancer no longer responds to standard treatment;
  • to find out what effects (good and bad) gemcitabine has when given directly into the cerebrospinal fluid (called intrathecal administration) in children and adults with neoplastic meningitis (cancer that has spread to the lining of the brain and spinal cord);
  • to determine if gemcitabine is beneficial to the patient;
  • to understand how gemcitabine is handled by the body after intrathecal administration.

Condition Intervention Phase
Meningitis
Neoplasms
Drug: Gemcitabine
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intrathecal Gemcitabine Therapy for Neoplastic Meningitis: A Phase I and Pharmacokinetic Study

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Asses the toxicity of intrathecally administered gemcitabine in a limited dosage escalation schedule. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Determination of the maximum tolerated dose of intrathecally administered gemcitabine. [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    The MTD of IT gemcitabine will be that dose at which less than 20% of patients experience DLT as defined earlier. Escalations are planned in groups of three patients, with an additional three patients to be added at the first indication of DLT.


Secondary Outcome Measures:
  • To define the plasma and CSF pharmacokinetics of gemcitabine and its major metabolite, 2', 2'-difluoro-deoxyuridine (dFdU) after intrathecal administration. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Documentation of any responses following intrathecal gemcitabine administration. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Investigate MMP expression in pediatric and adult patients with a variety of primary diseases. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: December 2001
Study Completion Date: April 2007
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intrathecal gemcitabine administration

Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.

Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.

Dose Levels and Dose Escalation:

Dose Level 1a: 5 mg

Dose Level 1b: 5 mg

Dose Level 2: 10 mg

Dose Level 3: 20 mg

Dose Level 4: 30 mg

Dose Level 5: 40 mg

Dose Level 6: 50 mg

Drug: Gemcitabine

Schedule

Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).

In the absence of disease progression or DLT, patients may proceed to consolidation.

Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.

Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year.

Other Name: Gemzar

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • at least 3 years of age.
  • Neoplastic meningitis secondary to an underlying leukemia/lymphoma or a solid tumor (including primary CNS tumors or carcinomas of unknown primary site) for which there is no conventional therapy. Patients with CNS leukemia/lymphoma must be refractory to conventional therapy, including XRT (i.e. 2nd or greater relapse). Neoplastic meningitis is defined as follows:

    • Leukemia/Lymphoma: CSF cell count > 5 uL AND evidence of blast cells on cytospin preparation or by cytology.
    • Solid tumor: Presence of tumor cells on cytospin preparation or cytology OR presence of meningeal disease on MRI scans.
  • Life expectancy of at least 6 weeks.
  • Patients > 10 years old: Karnofsky performance status of >/= 50%. Patients </=10 years old: Lansky performance status of >/= 50%.
  • Must have recovered from the acute neurotoxic effects of all prior chemo, immuno, or radiotherapy and must be without uncontrolled significant systemic illness (e.g. infection). Must not have received any systemic CNS-directed therapy within 3 weeks or craniospinal irradiation within 8 weeks prior to starting treatment on study. Must not have received any intrathecal therapy within 1 week prior to starting treatment on study.
  • Must have a platelet count >40,000/uL and HCT >30% and an ANC of > 1000/uL.
  • Must have adequate liver function, total bilirubin < 2.0 mg, SGPT < 5 times upper limits of normal; adequate renal function (serum creatinine < 2 times upper limits of normal for age).
  • Patients must have or be willing to have an intraventricular access device such as an Ommaya reservoir.

Exclusion Criteria:

  • Patients receiving other therapy (either intrathecal or systemic) designed to treat their leptomeningeal disease. However, patients receiving concomitant chemotherapy to control systemic disease or bulk CNS disease will be eligible, provided that the systemic chemotherapy is not a phase I agent, an agent that significantly penetrates the CSF, or an agent known to have serious unpredictable CNS side effects.
  • Nuclear Medicine CSF flow studies are required within the 2 weeks prior to study entry for all solid tumor patients. In leukemia/lymphoma patients a CSF flow study is only required if CSF analysis or an MRI suggests that there is a blockage to CSF flow. Patients with clinical evidence of obstructive hydrocephalus are not eligible for this protocol. Nor are patients with compartmentalization of CSF flow as documented by radioisotope Indium111 or Technetium99-DTPA flow eligible for this protocol. If a CSF flow block or compartmentalization is demonstrated, focal radiotherapy to the site of the block to restore flow followed by a repeat CSF flow study demonstrating clearing of the blockage is required for the patient to be eligible for the study.
  • Patients must not have clinically significant abnormalities of serum electrolytes, including calcium, magnesium, and phosphorus.
  • Patients with a ventriculoperitoneal (VP) or ventriculoatrial (VA) shunt are not eligible unless they are shunt-independent and there is evidence that their shunt is nonfunctional
  • Patients who have leukemia/lymphoma with a concomitant bone marrow relapse.
  • Women of childbearing age must not be pregnant or lactating. (Male and female patients who are fertile must be willing to use an effective means of birth control to avoid pregnancy.)
  • Must be free of uncontrolled infection except HIV (i.e., AIDS-related lymphomatous meningitis).
  • Must NOT be receiving any other investigational agents and must not have received any other investigational agent within 14 days prior to study treatment. The 14-day period should be extended if the investigational agent is known to have delayed toxicity.
  • Patients with impending spinal cord compression, CNS involvement requiring local XRT (e.g. optic nerve), or isolated bulky ventricular or leptomeningeal based lesions are not eligible.
  • Concomitant CNS radiation therapy is not permitted. (Patients are not permitted to receive radiation to any port that encompasses any part of the brain or spine while on study.) Patients may receive radiation therapy to extra-CNS sites, e.g. painful bone metastases not in the craniospinal axis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00074607

Locations
United States, Maryland
National Cancer Institute
Bethesda, Maryland, United States, 20892
United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Baylor College of Medicine
Texas Children's Hospital
University of Pittsburgh
Children's Hospital of Pittsburg
Seattle Children's Hospital
Mayo Clinic
Brown University
Investigators
Principal Investigator: Susan Blaney, MD Baylor College of Medicine
  More Information

Publications:
Responsible Party: Susan Blaney, Professor of Pediatrics-Hem-Oncology, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00074607     History of Changes
Obsolete Identifiers: NCT00039143, NCT00048243, NCT00052806
Other Study ID Numbers: H10564 IT Gemcitabine, I.T. Gemcitabine
Study First Received: December 16, 2003
Last Updated: November 9, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Baylor College of Medicine:
Neoplastic meningitis

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Meningeal Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Neoplasms
Meningeal Carcinomatosis
Meningitis
Central Nervous System Diseases
Central Nervous System Infections
Nervous System Diseases
Gemcitabine
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014